Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11446398 Regulated biocircuit systems

Patent 11446398 was granted and assigned to Obsidian Therapeutics on September, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Obsidian Therapeutics

0

Current Assignee

Obsidian Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Date of Patent

September 20, 2022

0

Patent Application Number

160928290

Date Filed

April 11, 2017

0

Patent Citations

US Patent 10221245 Treatment of cancer using humanized anti-CD19 chimeric antigen receptor

Patent Citations Received

US Patent 11975025 Viral vectors and use thereof in adoptive cellular therapy

0

US Patent 11945881 Neoantigens expressed in ovarian cancer and their uses

0

Patent Primary Examiner

Karen Cochrane Carlson

0

CPC Code

0

0

0

0

0

0

The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11446398 Regulated biocircuit systems

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool